FibroGen (NASDAQ:FGEN) posted its earnings results on Thursday. The biopharmaceutical company reported $1.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $1.75, Bloomberg Earnings reports. The company had revenue of $191.57 million during the quarter, compared to analyst estimates of $29.03 million. FibroGen had a net margin of 13.90% and a return on equity of 9.62%. FibroGen’s revenue for the quarter was up 335.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.28) earnings per share.
FGEN stock traded down $0.30 during trading on Friday, reaching $46.20. The company had a trading volume of 590,936 shares, compared to its average volume of 464,759. FibroGen has a 52 week low of $33.51 and a 52 week high of $62.00. The stock has a market cap of $4.01 billion, a P/E ratio of -44.85 and a beta of 1.86. The business’s 50 day moving average price is $45.66. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.16 and a current ratio of 6.16.
A number of analysts have recently weighed in on FGEN shares. Mizuho reiterated a “buy” rating and set a $65.00 target price on shares of FibroGen in a report on Sunday. Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 target price on shares of FibroGen in a report on Wednesday, May 29th. Zacks Investment Research lowered shares of FibroGen from a “buy” rating to a “hold” rating in a report on Monday, July 29th. ValuEngine lowered shares of FibroGen from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Piper Jaffray Companies reiterated a “positive” rating and set a $40.00 target price (down from $65.00) on shares of FibroGen in a report on Monday, May 27th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $61.14.
Hedge funds have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC increased its stake in shares of FibroGen by 150.0% during the first quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 300 shares in the last quarter. FTB Advisors Inc. bought a new position in shares of FibroGen during the first quarter valued at approximately $27,000. Manchester Capital Management LLC bought a new position in shares of FibroGen during the first quarter valued at approximately $39,000. Cornerstone Advisors Inc. increased its stake in shares of FibroGen by 672.8% during the first quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 693 shares in the last quarter. Finally, Quadrant Capital Group LLC bought a new position in shares of FibroGen during the first quarter valued at approximately $45,000. 66.51% of the stock is owned by institutional investors.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Story: What is total return in investing?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.